Comparative Study of Some New Naproxen Derivatives on the Liver and Kidney Tissues of Mice
Naproxen is a phenyl propionic acid that has anti-inflammatory, analgesic, and antipyretic effects with confirmed adverse effects on most body organs involve the stomach, intestine, liver, and kidneys. This study aimed to assess the analgesic effects of new naproxen derivatives (synthesized in other studies) and limited side effects by modifying their chemical structure by adding active groups to the parent compounds. We performed analysis of newly synthesized and administered naproxen-derived drugs on male albino mice (30-35 g) distributed into five groups; the first was named the negative control group. Four other groups administered one of the synthesized compounds of naproxen derivatives. The current study reported that the histopathological section of hepatocyte of mice treated orally with 250 mg/kg of naproxen for five days showed severe dilatation and congestion of central vein with necrosis of hepatic tissue with amyloid deposition in necrotic hepatic tissue with lymphocyte and Kupffer cells infiltration. On the other hand, the histopathological section of the liver of mice treated orally with 250 mg/kg of compound 4a for five days showing severe distraction and hemorrhage of hepatic tissue, while compound 5 showed severe necrosis of hepatic tissue with vacuolation, necrosis of hepatic tissue and inflammatory cell infiltration in rats. At the same time, the results revealed clear improvement in the liver of mice who received 4b compound via regeneration of hepatic tissue by the formation of multiple granulomas around the newly formed blood vessels and immune cell stimulation. In addition to naproxen appears amyloid deposition in necrotic renal tissue while 4b orally appears regeneration of malignant tissue by the formation of granuloma around newly formed blood vessels. Our research concludes that 4b related new derivative is a valuable focus for future seeks and potentially clinical implementation due to its relatively high efficacy and minimal adverse effects compared to another tested compound in our study.
Keywords: naproxen, mice, nonsteroidal anti-inflammatory drug.
BINDU S., MAZUMDER S., and BANDYOPADHYAY U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochemical pharmacology, 2020: 114-147.
GIWA A. and JAMIU M. Utilization of Non-Steroidal Anti-Inflammatory Drugs among Physicians in a Nigerian Tertiary Health Facility. 2018.
TURINI M. E. and DUBOIS R. N. Cyclooxygenase-2: a therapeutic target. Annual Review of Medicine, 2002, 53(1): 35-57.
MAZI S. I. Studying COX-2 in the cardiovascular system using a transcriptomic approach. 2017.
KISHORE N., KUMAR P., SHANKER K., and VERMA A. K. Human disorders associated with inflammation and the evolving role of natural products to overcome. European journal of medicinal chemistry, 2019, 179: 272-309.
MOHAMMED Q. A. Protective role of vitamin–TPGS to overcome oxidative stress induced by dipping of sheep with cypermethrin. Plant Archives, 2020, 20(1): 1105-1109.
JASIM A.M., HASAN H. F., and AWADY M. J. Preparation of Vorapaxar loaded with Vitamin E TPGS and PVA emulsified PLGA nanoparticles In vitro studies. Research Journal of Pharmacy and Technology, 2019, 12(9): 4503-4510.
PANI N. R., NATH L. K., and BHUNIA B. Formulation, development, and optimization of immediate release nateglinide tablets by factorial design. Drug Discoveries and Therapeutics, 2010, 4(6): 453-458.
BALAMURALIDHARA V., PRAMODKUMAR T. M., SRUJANA N., VENKATESH M. P., GUPTA N. V., KRISHNA K. L., and GANGADHARAPPA H. V. pH-sensitive drug delivery systems: a review. American Journal of Drug Discovery and Development, 2011, 1(1): 24-48.
VINAROV Z., ABDALLAH M., AGUNDEZ J. A. G., ALLEGAERT K., BASIT A. W., BRAECKMANS M., CEULEMANS J., CORSETTI M., GRIFFIN B. T., GRIMM M., KESZTHELYI D., KOZIOLEK M., MADLA C. M., MATTHYS C., MCCOUBREY L. E., MITRA A., REPPAS C., STAPPAERTS J., STEENACKERS N., TREVASKIS N. L., VANUYTSEL T., VERTZONI M., WEITSCHIES W., WILSON C., and AUGUSTIJNS P. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences, 2021, 162: 105812.
NUSSMEIER N. A., WHELTON A. A., BROWN M. T., LANGFORD R. M., HOEFT A., PARLOW J. L., BOYCE S. W., and VERBURG K. M. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New England Journal of Medicine, 2005. 352(11): 1081-1091.
SOLOMON S. D., MCMURRAY J. J. V., PFEFFER M. A., WITTES, ROBERT FOWLER, PETER FINN, WILLIAM F ANDERSON, ANN ZAUBER J., HAWK E., and BERTAGNOLLI M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine, 2005, 352(11): 1071-1080.
ZARRAGA I. G. E. and SCHWARZ E. R. Coxibs and heart disease: what we have learned and what else we need to know. Journal of the American College of Cardiology, 2007, 49(1): 1-14.
WALLACE J. L., IANARO A., and DE NUCCI G. Gaseous mediators in gastrointestinal mucosal defense and injury. Digestive diseases and sciences, 2017, 62(9): 2223-2230.
ARARUNA, M.E., SILVA P., ALMEIDA M., RÊGO R., DANTAS R., ALBUQUERQUE H., CABRAL I., APOLINÁRIO N., MEDEIROS F., MEDEIROS A., and SANTOS V. Tablet of Spondias mombin L. Developed from Nebulized Extract Prevents Gastric Ulcers in Mice via Cytoprotective and Antisecretory Effects. Molecules, 2021, 26(6): 1581.
DA SILVA D. M., MARTINS J. L. R., DE OLIVEIRA D. R., FLORENTINO I. F., DA SILVA D. P. B., DOS SANTOS F. C. A., and COSTA E. A. Effect of allantoin on experimentally induced gastric ulcers: pathways of gastroprotection. European Journal of Pharmacology, 2018, 821: 68-78.
JASIM A. M., ALHTHEAL E. D., RAHEEM S. S., RAWAA K. J., and HAMA A. Characterization and Synthesis of Selenium-TPGS Nanoparticles for Target Delivery Clove to Minimize Cytogenic and Liver Damage Induced in Adult Male Rats. Nano Biomed, 2021, 13(2): 127-136.
BROWN R.W., CHENG Y.-C. N., HAACKE E. M., THOMPSON M. R., and VENKATESAN R. Magnetic resonance imaging: physical principles and sequence design. 2014, John Wiley and Sons.
AHSAN H., AHAD A., IQBAL J., and SIDDIQUI W. A. Pharmacological potential of tocotrienols: a review. Nutrition and metabolism, 2014, 11(1): 1-22.
GRAVIS M. and MYOTONIAS N. Neuromuscular Diseases. Neurological Diseases and Pregnancy: A Coordinated Care Model for Best Management, 2018.
DE PACE N. L. and COLOMBO J. Mind-Body Wellness Program Benefits, in Clinical Autonomic and Mitochondrial Disorders. 2019, Springer.
FORNAI M., ANTONIOLI L., PELLEGRINI C., COLUCCI R., SACCO D., TIROTTA E., NATALE G., BARTALUCCI A., FLAIBANI M., RENZULLI C., GHELARDI E., BLANDIZZI C., and SCARPIGNATO C. Small bowel protection against NSAID-injury in rats: effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. Pharmacological Research, 2016, 104: 186-196.
JASIM A. M. and HASAN H. F. Evaluation of Vorapaxar and TPGS-PLGA loading Vorapaxar to reduced apoptosis and liver damage in atherosclerosis male rats. Iraqi National Journal of Chemistry, 2019, 19(1).
AWNI K. J., ABOKTIFA M. A., SALMAN M. A., and JASIM A. M. Characterization and Synthesis of New Model of Derivative Colonazepam and Clinical Trial to Inspection of Adverse Effect in Male Mice. In IOP Conference Series: Earth and Environmental Science, 2020. IOP Publishing.
RODRIGUES I. and NAEHRER K. A three-year survey on the worldwide occurrence of mycotoxins in feedstuffs and feed. Toxins, 2012, 4(9): 663-675.
ABBAS A. H. Synthesis, Characterization and Anti-Inflammatory Evaluation of New Potentially Active Naproxen Hydrazones. 2015, University of Baghdad.
MOORE N., POLLACK C., and BUTKERAIT P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Therapeutics and Clinical Risk Management, 12, 2015: 1061.
- There are currently no refbacks.